Vaderis Therapeutics AG

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)	Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, cardiovascular disorder, hematologic disorder, hemorrhagic disease, hereditary hemorrhagic telangiectasia, telangiectasis, vascular disorder, vascular hemostatic disease, vascular malformation	Recruiting	Phase 3	2026-09-17	NCT07743671
Effect of a Known P-glycoprotein (P-gp) Inhibitor, Itraconazole, on the Pharmacokinetics (PK) of Engasertib	Healthy Participants	Not yet recruiting	Phase 1	2026-09-02	NCT07800429
Assess Safety and Efficacy of VAD044 in HHT Patients	Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, arteriovenous hemangioma/malformation, cardiovascular disorder, hematologic disorder, hemorrhagic disease, hereditary hemorrhagic telangiectasia, telangiectasis, vascular disorder, vascular hemostatic disease, vascular malformation	Active, not recruiting	Phase 1 / Phase 2	2026-03-17	NCT05406362

Clinical trials